FOXO4-DRI

Preclinical

FOXO4-D-Retro-Inverso Peptide

Aliases
FOXO4-DRI, Proxofim
Administration
Subcutaneous injection (preclinical/animal research only)

Timing

A general projection of what people report noticing over time, based on the known mechanism and reported use patterns. It is not a guarantee and individual experience varies considerably.

  1. 1

    1–2 Weeks

    As a preclinical-only compound with no human dosing history, there is no established human timeline for felt effects at this stage.

  2. 2

    3–4 Weeks

    Animal studies suggest measurable senescent cell reduction can occur within this timeframe, though this has not been confirmed in humans.

  3. 3

    5–7 Weeks

    No human data exists to describe a typical experience at this stage.

  4. 4

    8–10 Weeks

    No human data exists to describe a typical experience at this stage.

  5. 5

    11–15 Weeks

    No human data exists to describe a typical experience at this stage.

  6. 6

    16–20 Weeks

    No human data exists to describe a typical experience at this stage.

  7. 7

    21–24 Weeks

    No human data exists to describe a typical experience at this stage; any real-world timeline remains unknown pending human trials.

⚠️ Research context only. This is not medical advice and results are not guaranteed.